Samples (2 μL) were diluted 1:10 in a 0.5-mL microtube (Sarstedt AG&Co, Nümbrecht, Germany) containing Cytokine Assay Buffer (Merck Millipore, Millipore Iberica, Madrid, Spain) and frozen at −80°C until analysis. A commercial immune-bead based assays in a Luminex IS-100 (Luminex Corporation, Austin, TX) was used to analyze 16 molecules. The concentrations of epidermal growth factor (EGF), CX3CL1/fractalkine, interferon (IFN)-γ, IL-10, IL-12p70, IL-17A, IL-1β, IL-1RA, IL-2, IL-6, CXCL8/IL-8, CXCL10/IP-10, CCL5/RANTES, TNF-α, and VEGF were measured simultaneously with a 15-plex assay (HCYTO-60K 15X-Milliplex, Millipore Iberica, Madrid, Spain). Matrix metalloproteinase (MMP)-9 concentration was measured in a separate assay with a MMP-9 single-plex assay (HMMP2-55K Panel 2; Milliplex, Millipore Iberica). The samples were analyzed following the manufacturer's protocol. Briefly, 10 μL of the 1:10 diluted sample were incubated under agitation overnight at 4°C with beads coated with antibodies specific for each molecule. After washing, beads were incubated with biotinylated human antibodies for 1 hour, followed by incubation with streptavidin-phycoerythrin for 30 minutes. Standard curves were used to convert fluorescence units to concentration units (pictograms/milliliter). The minimum detectable concentrations (in pictograms/milliliter) for molecules analyzed were IFN-γ and TNF-α, 0.1; CXCL8/ IL-8 and IL-17A, 0.2; IL-2, IL-6, and IL-10, 0.3; IL-1β, and IL-12p70, 0.4; CCL5/RANTES, 1; CXCL10/IP-10, 1.2; EGF, 2.7; IL-1RA, 2.9; VEGF, 5.8; CX3CL1/Fractalkine, 6; and MMP-9, 10. Data were stored and analyzed with the Bead View Software (Upstate-Millipore Corporation, Watford, UK). In some samples, the assayed molecule was undetectable. To include those samples in the statistical analysis, we assigned each the minimum detectable value (provided by the assay manufacturer). However, molecules that were detected in less than 30% of the samples were not further analyzed.